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Abstract 
Gastro-oesophageal reflux disease (GORD) develops when reflux of gastric content causes 
troublesome symptoms or complications. The main symptoms are heartburn and acid regurgitation 
and complications include oesophagitis, strictures, Barrett’s oesophagus and oesophageal 
adenocarcinoma. In addition to hereditary influence, GORD is associated with lifestyle factors, mainly 
obesity. Tobacco smoking is regarded as an aetiological factor of GORD, while alcohol consumption is 
considered a triggering factor of reflux episodes and not a causal factor. Yet, both tobacco smoking 
and alcohol consumption can reduce the lower oesophageal sphincter pressure, facilitating reflux. In 
addition, tobacco smoking reduces the production of saliva rich in bicarbonate, which is important 
for buffering and clearance of acid in the oesophagus. Alcohol also has a direct noxious effect on the 
oesophageal mucosa, which predisposes to acidic injury. Tobacco smoking cessation reduces the risk 
of GORD symptoms and avoidance of alcohol is encouraged in individuals where alcohol 
consumption triggers reflux. 
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A. Introduction 
Gastro-oesophageal reflux disease (GORD) is defined as a condition which develops when reflux of 
gastric content causes troublesome symptoms or complications [1]. The main symptoms are 
heartburn (a burning sensation behind the breastbone) and acid regurgitation (a sour taste in the 
mouth or throat) [2]. These symptoms are experienced occasionally by most people in the general 
population without being regarded as troublesome, and throughout the population there is a 
continuum of frequency and severity of reflux symptoms. Mild symptoms occurring two or more 
days a week or moderate to severe symptoms occurring more than one day a week are often 
considered troublesome and usually affect the health related quality of life [3, 4]. In epidemiological 
research, GORD is defined as at least weekly heartburn or regurgitation [5]. 
GORD is highly prevalent in most parts of the world. In Europe, America and Australia the 
prevalence is between 9% and 28%, while in East Asia the prevalence is lower, between 3% and 8% 
[6]. The prevalence is higher in more recent studies and seems to be increasing over time in the same 
population [7]. The incidence of GORD is about 5 per 1000 person-years [6].  
Complications of GORD include mucosal erosions (oesophagitis), peptic strictures, intestinal 
metaplasia (Barrett’s oesophagus) and oesophageal adenocarcinoma. In addition, several extra-
oesophageal manifestations might be associated with GORD, e.g. chronic cough, laryngitis, asthma, 
pneumonia and dental erosions. These manifestations are believed to be due to laryngopharyngeal 
reflux and micro aspirations to the lungs or due to reflexes mediated by the vagal nerves [8]. 
However, the extra-oesophageal manifestations are usually multifactorial and GORD is rarely the sole 
cause [1]. 
In clinical practice, the diagnosis of GORD is typically based on cardinal symptoms of 
heartburn or regurgitation and symptom relief after a short course of acid-inhibiting medical 
treatment, usually a proton pump inhibitor (PPI) [9]. If the symptoms do not resolve, the patient may 
be referred to an upper gastrointestinal endoscopy where oesophagitis, peptic strictures and 
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Barrett’s oesophagus are diagnostic [10]. However, these complications are not sensitive markers of 
GORD. In a Swedish endoscopy survey, oesophagitis was present only in 29% of participants with 
weekly heartburn or regurgitation [11]. If the endoscopy is not diagnostic, a 24 hour oesophageal pH 
measurement might reveal pathological acidic reflux (fraction time with oesophageal pH <4) [12]. 
The pH measurement can also be combined with an impedance measurement to detect weakly 
acidic or non-acidic reflux, the latter typically refractory to acid-inhibiting medical treatment [13]. 
 
A. Anatomy and physiology 
The anatomy and physiology of the gastro-oesophageal junction is of great importance in GORD.  The 
lower oesophageal sphincter (LOS), the angle between the left side of the distal oesophagus and the 
proximal stomach (the fundus) where the oesophagus enters the stomach (the angle of His) the 
narrow angle where the oesophagus enters the stomach (the angle of His) and the tight opening 
(hiatus) of the crural diaphragm where the oesophagus enters the abdomen together create an anti-
reflux barrier [14]. When reflux appears the refluxed material is cleared from the oesophagus by 
gravity and peristaltic movements [15] and residual acid is neutralised by swallowed saliva rich in 
bicarbonate [16]. In addition, tight junctions in the oesophageal epithelia and the lipid-rich matrix in 
the intercellular spaces protect the mucosa from acidic damage and bicarbonate in the extracellular 
space buffers acid that reaches deeper than the mucosal surface [17, 18]. 
 
A. Pathophysiology 
A sliding hiatal hernia is an anatomical disruption of the anti-reflux barrier where a portion of the 
proximal stomach is located in the thoracic cavity. Such herniation counteracts the flap valve 
mechanism created by the angle of His [19]. In addition, the hernia impairs clearance of acid from the 
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oesophagus by trapping acid in the hernia [20, 21]. A large hernia also impairs the pinchcock-like 
action of the diaphragm on the oesophagus [22]. 
The most common mechanism of reflux is transient lower oesophageal sphincter relaxations 
(TLOSRs) [15, 23]. TLOSRs are relaxations of the LOS and the crural diaphragm not triggered by 
swallowing [24], which is a physiological mechanism that allows belching [25, 26]. In GORD patients, 
there is an increased pressure gradient over the gastro-oesophageal junction and increased 
compliance of the junction which facilitates reflux when TLOSRs appear [27, 28]. In some GORD 
patients the LOS resting pressure is hypotensive [29], which allows reflux to occur more easily when 
the LOS pressure is overcome by an abrupt increase in the intra-abdominal pressure, i.e. strain-
induced reflux [23, 30]. 
B. Tobacco smoking 
Tobacco smoking can induce gastro-oesophageal reflux by reducing the LOS resting pressure, as 
shown by several studies from the 1970s [31-33]. In a study of six male healthy volunteers without 
GORD, inhalation of cigarette smoking decreased the LOS pressure 37% within two to three minutes, 
while puffing  an unlit cigarette did not induce any change in the LOS pressure [31]. The pressure 
remained low until smoking was stopped and then the pressure returned towards normal. In a study 
evaluating 25 daily smokers with heartburn, cigarette smoking caused a fall in the LOS pressure with 
41% within one to four minutes [32]. The pressure returned to baseline within three to eight minutes 
after having stopped smoking and puffing an unlit cigarette did not change the LOS pressure. In this 
study, pH measurements also showed increased reflux during and after tobacco smoking. In a study 
of 10 asymptomatic individuals and 10 symptomatic GORD patients, the LOS pressure was not 
significantly different at baseline, but was reduced by 19% and 21%, respectively, during cigarette 
smoking [33]. In a study of nine smokers without GORD and nine smokers with GORD, the majority of 
reflux episodes occurred during coughing and deep inspiration, associated with abrupt increased 
intra-abdominal pressure which overcame the LOS pressure [34]. The probable mechanism of 
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tobacco induced LOS pressure reduction is blocking of cholinergic receptors by nicotine and 
subsequent relaxation of the circular LOS muscle fibres [35, 36]. 
Tobacco smoking is also associated with prolonged acid clearance time, probably due to 
reduced salivary secretion rate and bicarbonate concentration [37, 38]. In a study of eight non-
smokers and 16 daily cigarette smokers without GORD, smoking resulted in an immediate 
prolongation of the acid clearance time and reduced salivary secretion rate [37]. Moreover, the acid 
clearance time was prolonged and the salivary secretion rate was lower among smokers how 
refrained from smoking during the study compared to non-smokers, suggesting a long-lasting 
negative effect of tobacco smoking. There was also a parallel, but less pronounced, reduction in the 
bicarbonate concentration among smokers. The reduced acid clearance time is most likely the result 
of reduced salivary secretion rate. In a another study examining 11 daily smokers without GORD 
symptoms, salivary bicarbonate secretion increased following tobacco smoking cessation, suggesting 
a benefit in GORD patients [38]. 
B. Alcohol consumption 
Similar to tobacco smoking, alcohol consumption might also reduce the LOS resting pressure. In a 
study of 20 healthy volunteers without GORD, white wine (8% alcohol) reduced the LOS resting 
pressure, but not red wine (12% alcohol), even with a higher alcoholic percentage in the red wine 
consumed [39]. There was no difference in the LOS resting pressure between red wine and tap-
water. Consumption of white wine was also followed by increased fraction time with oesophageal pH 
<4. Red wine also induced GORD symptoms and reflux episodes, but not a pathological fraction time 
of pH <4 in the oesophagus. In a study of 24 healthy volunteers, beer (7% alcohol) also increased the 
median fraction time of pH <4 compared to water, but the values were still within the normal range 
[40]. In this study, an ethanol solution of 7.5% was also compared to tap-water, without showing any 
difference in the fraction time of pH <4. These findings suggest that other ingredients in wine and 
beer rather than alcohol promotes reflux among consumers of these alcoholic-containing beverages.  
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In a study of 12 healthy volunteers without GORD, pH measurements showed significantly 
increased reflux after ingestion of 180 ml vodka compared with 180 ml water [41]. In a study of 17 
healthy volunteers without GORD, ingestion of 120 ml whiskey (40% alcohol) induced supine nightly 
reflux events assessed by pH measurements that were not apparent during the control night after a 
placebo drink [42]. A study of acute alcohol intoxication (300 ml whiskey with 43% alcohol during one 
hour) in twelve volunteers without GORD showed reduced incidence of primary peristalsis in the 
distal oesophagus, but the oesophageal motor function was normal eight hours after the intoxication 
[43]. One of the volunteers experienced transient heartburn after the ingestion. Deterioration of 
oesophageal peristalsis can be found in patients with alcoholic neuropathy [44]. However, this 
deterioration could have multiple causes related to alcoholism.  
Alcohol might also have direct effects on the oesophageal mucosa. In a study of rabbits, an 
oesophageal mucosal exposure to 10% ethanol had a direct noxious effect on the epithelium, which 
predisposed to acidic injury [45]. 
 
A. Aetiology 
Large population-based cohort studies provide the best evidence of the aetiological factors of GORD. 
The population-based cohort design is less prone to selection bias compared to e.g. hospital-based 
studies or case-control studies. Large studies also provide more precise estimates of associations 
with sufficient statistical power to detect weaker associations and to conduct robust sub-analyses. In 
recent population-based studies, GORD is typically defined as at least weekly symptoms of heartburn 
or regurgitation.  
The aetiology of GORD includes both genetic and lifestyle-related factors. The risk of GORD is 
increased within families [46] and there is a higher concordance in the prevalence of GORD in 
monozygotic over dizygotic twin pairs, suggesting a 23% to 39% genetic influence [47, 48]. Obesity is 
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the strongest lifestyle-related risk factor of GORD, especially visceral obesity [49-52]. High dietary 
fibre intake and moderate physical exercise, on the other hand, seem to protect against the 
development of GORD [53].   
B. Tobacco smoking 
In most studies, tobacco smoking has been associated with an increased risk of developing GORD 
(Table) [46, 47, 52-60]. The association between tobacco smoking and GORD is seemingly of weak or 
moderate strength with most reported odds ratios (ORs) below 2. In the largest study on the topic, a 
nested case-cohort study from Norway with 43,363 participants, the adjusted ORs for GORD were 1.7 
(95% CI 1.5 to 1.9) among daily smokers with more than 20 years of smoking history and 1.6 (95% CI 
1.3 to 2.0) among smokers with a lifetime number of more than 200,000 cigarettes [53]. A small case-
control study from Albania with 845 participants reported very high risk estimates for GORD, with 
adjusted OR of 9.8 (95% CI 4.2 to 22.7) among former smokers and 29.3 (95% CI 13.9 to 61.2) among 
current smokers [60]. Both increased duration and amount of tobacco smoking are dose-
dependently associated with an increased risk of GORD [53, 54, 56].  
In a Norwegian cohort study with 14,916 participants, the adjusted OR of new-onset GORD 
was 1.4 (95% CI 1.1 to 1.8) among previous smokers and 1.3 (95% CI 1.0 to 1.7) among current 
smokers [52]. In this study, also individuals who quit smoking during the study period had remaining 
increased risk of new-onset GORD, with adjusted of OR 1.7 (95% CI 1.3 to 2.3), but this association 
was explained by gain in weight upon quitting smoking. In a smaller longitudinal case-control study 
from the United Kingdom with 3418 participants, the risk of new-onset GORD following tobacco 
smoking did not reach statistical significance at the 1% level, with adjusted OR of 1.3 (99% CI 0.9 to 
2.0) [61]. Several smaller studies have failed to find any association between tobacco smoking and 
GORD [61-64], but this could be due to limited statistical power. 
B. Alcohol consumption 
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Most studies have failed to identify any aetiological association between alcohol consumption and 
GORD (Table) [47, 52, 53, 62-64]. Some data, however, indicate that high alcohol intake is 
moderately associated with GORD. In a case-control study from the United States, intake of more 
than seven drinks per week was associated with increased risk of GORD, with an adjusted OR of 1.9 
(95% CI 1.1 to 1.3) [46]. A Japanese case-control study found that heavy drinkers (more than 38 
mL/day) had an increased risk of GORD, with an adjusted OR of 1.6 (95% CI 1.1 to 2.3) [54]. A case-
control study from the United Kingdom reported an association between excessive alcohol 
consumption (more than 30 units per week for men and more than 20 units per week for women) 
and GORD, with an adjusted OR of 3.0 (95% CI 1.5 to 6.1) [55]. An Albanian case-control study found 
that moderate to heavy alcohol intake was associated with GORD, with an adjusted OR of 1.8 (95% CI 
1.1 to 3.1) [60].  
However, the largest studies have not identified any association between alcohol 
consumption and GORD [52, 53]. In the largest study available, a nested case-cohort study from 
Norway with 43,363 participants, more than ten occasions with alcohol consumption during the last 
two weeks were not associated with any increased risk of developing GORD, adjusted OR 1.0 (95% CI 
0.8 to 1.3), and there was no dose-response association with increasing consumption (p for trend 
0.54) [53]. In a Swedish case-control study of 27,717 twins, increasing alcohol intake even indicated a 
dose-dependent decreased risk of GORD in the monozygotic co-twin control comparison among 
women (p for trend 0.0093), with adjusted OR of 0.31 (95% CI 0.11 to 0.84) with an alcohol intake of 
more than 2400 grams per month [56]. However, when the consumption of beer, wine and spirits 
was analysed separately, no association with GORD was evident. This, together with lack of such 
association among men in the same study, suggests that chance might be an explanation of the 
inverse association.  
A prospective Norwegian cohort study with 14,916 participants found that at least weekly 
consumption of alcohol did not influence the risk of new-onset GORD, with an adjusted OR of 0.9 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Best Practice & Research Clinical Gastroenterology 
10 
 
(95% CI 0.7 to 1.2) [52], and a longitudinal case-control study from the United Kingdom with 3418 
participants found no increased risk of new-onset GORD, with adjusted OR of 0.6 (95% CI 0.3 to 1.0) 
[65]. 
 
A. Management 
The management of patients with GORD can be based on lifestyle modification, medical treatment, 
and anti-reflux surgery. 
B. Lifestyle modification 
The best evidence of lifestyle modification in GORD is for weight loss, tobacco smoking cessation, 
head of bed elevation during sleep, very low-carbohydrate diet, diet rich in dietary fibres and 
avoiding meals before bedtime [9, 66-70]. In addition, it is recommended to avoid dietary factors 
whenever these are perceived as triggering factors of reflux episodes by the individual patient, i.e. 
coffee, alcohol, chocolate, peppermint, citrus, carbonated drinks and spicy foods. 
C. Tobacco smoking cessation 
In a prospective population-based cohort study form Norway including 29,610 participants, smoking 
cessation was associated with decreased heartburn and acid regurgitations in normal weight 
individuals using acid-inhibiting medical treatment, compared to participants who continued smoking 
daily, with an adjusted OR of 5.7 (95% CI 1.4 to 23.6) [71]. However, smoking cessation was not 
associated with improvement in GORD in overweight (BMI between 25.0 and 29.9) or obese (BMI 
above 30.0) individuals, with adjusted ORs of 1.2 (95% CI 0.6 to 2.7) and 1.3 (95% CI 0.5 to 3.2), 
respectively. This could be explained by the strong association between obesity and GORD, 
compared to the weaker association between tobacco smoking and GORD. In obese individuals, the 
pathophysiological mechanism driving reflux might be dictated by weight, with tobacco smoking 
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playing a minor or no role, while in normal weight individuals with GORD, tobacco smoking might be 
a more important pathophysiological factor [71]. 
 In addition, two small studies have assessed the immediate effects of cigarette smoking 
cessation on pH measurements in GORD patients [72, 73]. In eight male daily smokers with GORD, 
abstaining from cigarette smoking for one day decreased the number of reflux episodes in the 
upright position, but not the total oesophageal acid exposure [72]. In another study, examining 14 
daily smokers with GORD, cigarette smoking increased the fraction time of pH<4 and reduced the 
frequency of heartburn after abstaining for smoking for 48 hours [73]. 
C. Alcohol abstinence 
Based on the available pathophysiological and aetiological evidence, alcohol is mainly considered an 
instant trigger of reflux, rather than a causal risk factor of GORD, and no long-term interventional 
studies of alcohol abstinence in GORD exist. 
In the current clinical management guidelines avoidance of alcohol use as a treatment of 
GORD has little or no place [9, 68-70]. However, whenever the individual patient experiences alcohol 
consumption as a trigger of GORD symptoms, alcohol abstinence or reduction of alcohol use 
moderation is recommended.  
B. Medical and surgical treatment 
Medical treatment of GORD mainly consists of acid-inhibiting treatment aimed at reducing the acidity 
of the refluxed content. With mild and infrequent reflux symptoms without any signs of 
complications, antacids, sucralphate or alginate are recommended. These medications are rapidly 
acting, but the duration of the effect is short [69]. With more severe and frequent symptoms of 
GORD or in individuals with oesophagitis or Barrett’s oesophagus, proton pump inhibitors (PPIs) are 
recommended and long-term use is often needed to prevent recurrence [74] and possibly prevent 
adenocarcinoma [75]. In the long-term time frame (26 to 52 weeks), PPI therapy reduces the risk of 
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relapsing oesophagitis and controls symptoms better than H2-reseptor antagonists, which in turn are 
better than placebo [74, 76, 77].  
Medical treatment may last for an indefinite period of time with high costs for patients and 
society [78, 79]. In addition, long-term and potent acid inhibition with PPIs may be associated with 
specific adverse effects, including secondary hypergastrinaemia with rebound hypersecretion of acid 
upon withdrawal of PPIs [80, 81]. Moreover, hypoacidity is associated with increased risk of 
infections and malabsorption [82-87]. 
Anti-reflux surgery with fundoplication is presently mainly used for selected patients. 
Fundoplication repairs the reflux barrier and controls both acid and non-acid reflux, including bile 
salts and pancreatic juice [88], which could be beneficial for patients intolerant of PPIs or with 
persistent troublesome regurgitation despite PPI therapy [69]. Fundoplication is as effective as 
treatment with PPIs in preventing recurrence of oesophagitis and resolving of heartburn, and better 
in the controlling of acid regurgitation [89, 90]. On the other hand, patients who have undergone 
surgery have higher rates of dysphagia, bloating and flatulence [89, 90]. 
 
A. Practice Points 
• Tobacco smoking cessation should be advised to all smokers with GORD. 
• Avoidance or moderation of alcohol consumption should be advised to individual patients 
with GORD if the patient perceives alcohol consumption as a triggering factor of reflux 
episodes. 
 
A. Research Agenda 
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• The documentation of treatment effect of tobacco smoking cessation or alcohol abstinence 
in GORD is sparse. 
• Randomized clinical trials assessing the role of tobacco smoking cessation and alcohol 
consumption in the aetiology of GORD will never be performed due to the ethical problems 
with continued use of tobacco and alcohol in a trial. 
• Large prospective population-based observational studies should be performed to assess 
whether tobacco smoking cessation and alcohol abstinence are associated with reduced 
symptoms and complications of GORD. Ideally, such studies should include endoscopic 
assessments and pH and impedance measurements.  
• Non-randomized intervention studies should also be performed targeting alcohol and 
smoking behaviours as part of lifestyle modifications in patients with GORD. 
 
A. Summary 
Tobacco smoking and alcohol consumption reduces the LOS resting pressure. In addition, tobacco 
smoking reduces salivary bicarbonate secretion and increases acid clearance time in the oesophagus. 
Alcohol has direct noxious effects on the oesophageal mucosa, predisposing for acidic injury. 
Tobacco smoking is a causal aetiological factor of GORD, while alcohol consumption is a triggering 
factor of reflux episodes among individuals with GORD, but not a risk factor for developing GORD. 
Tobacco smoking cessation may reduce GORD symptoms. However, tobacco smoking is only a weak 
risk factor of GORD and other lifestyle modifications, including weight loss, and medical treatment 
are usually of greater importance in the treatment of GORD. Whether tobacco smoking cessation 
prevents or improves the complications of GORD is not known. No long-term interventional studies 
of alcohol abstinence in GORD exist. Ideally, randomized clinical trials of tobacco smoking cessation 
and alcohol abstinence should be performed to answer the question of the effect on GORD, including 
symptoms and complications, but such trials are not feasible due to the ethical problems. Large and 
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prospective population-based cohort studies and non-randomized intervention studies targeting 
alcohol and smoking behaviours are more realistic alternatives.  
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Table. Risk of gastro-oesophageal reflux disease (GORD) with tobacco smoking and alcohol consumption 
First author Pub. 
year 
Country Study 
design 
Number of 
participants 
Response 
rate 
Number 
of cases 
Data Case 
definition 
Prevalent 
or 
incident 
cases 
Risk of GORD with  
tobacco smoking 
Risk of GORD with 
alcohol consumption 
Adjustments* 
Locke
46
 1999 USA Population-
based cross 
sectional 
case-control 
1524 72% 872 Questionnaire At least 
weekly 
heartburn or 
acid 
regurgitation 
during the 
prior 
year 
Prevalent Never cigarette use, OR 1.0 
(reference); current 
cigarette use, OR 1.3 (95% 
CI 0.8-2.1); past cigarette 
use, OR 1.6 (95% CI 1.1-2.3). 
Alcohol drinks per week: 
None, OR 1.0 (reference); 
1-2, OR 1.0 (95% CI 0.6-
1.6); 3-6, OR 1.3 (95% CI 
0.8-2.1); 7+, OR 1.9 (95% 
CI 1.1-3.3). 
Age, gender, 
psychosomatic 
symptom 
checklist score, 
BMI, 
smokingcigarette 
use, alcohol use, 
coffee use, 
ASA/NSAIDs, 
relative and 
spouse history. 
Mohammed
47
 2003 UK Population-
based cross 
sectional 
case-control 
twin 
5032 56% 906 Questionnaire At least 
weekly 
heartburn or 
acid 
regurgitation 
during the 
past year 
Prevalent Ever smoked, OR 1.31 (95% 
CI 1.10–1.54). 
Excess alcohol intake (>28 
units/week for men, >21 
units/week for women), 
OR 0.99 (95% CI 0.99–
1.00). 
Age, smoking, 
alcohol, BMI, 
drug therapy, 
sex, handedness, 
parental family 
history of upper 
gastrointestinal 
disease. 
Watanabe
54
 2003 Japan Population-
based cross 
sectional 
case-control 
4188 86% 276 Questionnaire At least twice 
weekly 
heartburn or 
acid 
regurgitation 
the past one 
year 
Prevalent Lifelong non-smokers, OR 
1.00 (reference); former 
smokers, OR 1.32 (95% CI 
0.89–1.96); current 
smokers, OR 1.35 (95% CI 
1.01–1.82). 
 
Pack-years of cigarette 
smoking: 0, OR 1.0 
(reference); 0.1-20.0, OR 
1.29 (95% CI 0.87-1.90); 
>20.1, OR 1.45 (95% CI 
1.04–2.04); p for trend 
0.034. 
Daily alcohol drinking 
(mL/day): non-drinkers, 
OR 1.25 (95% CI 0.85–
1.85); light drinkers (0–
15), OR 1.00 (reference); 
moderate drinkers (16–
37), OR 1.47 (95% CI 
1.01–2.15); heavy 
drinkers (38–), OR 1.60 
(95% CI 1.09–2.34). 
Age, BMI, 
smoking habits, 
daily alcohol 
consumption. 
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Nilsson
53
 2004 Norway Population-
based 
nested case-
cohort 
43363 71% 3153 Questionnaire Severe (95% 
at least 
weekly) 
heartburn or 
acid 
regurgitation 
during the 
previous 12 
months  
Prevalent Daily smoking (years): <1, 
OR 1.0 (reference); 1–5, OR 
1.2 (95% CI 0.9–1.6); 6–10, 
OR 1.5 (95% CI 1.2–1.8); 10–
20, OR 1.7 (95% CI 1.4–1.9); 
>20, OR 1.7 (95% CI 1.5–
1.9); p for linear trend 
<0.0001.  
 
Lifetime number of 
cigarettes smoked 
(thousands): <0.1, OR 1.0 
(reference); 0.1–25, OR 1.1 
(95 % CI 0.9–1.4); >25–50, 
OR 1.5 (95% CI 1.3–1.8); 
>50–100, OR 1.6 (95% CI 
1.4–1.8); >100–200, OR 1.6 
(95% CI 1.4–1.9); >200, OR 
1.6 (95% CI 1.3–2.0); p for 
linear trend <0.0001. 
Occasions of spirits, wine, 
or beer consumption 
during last two weeks: 
None, OR 1.0 (reference); 
1–4, OR 0.9 (95 % CI 0.8–
1.0); 5–10, OR 0.9 (95% CI 
0.7–1.2); >10, OR 1.0 
(95% CI 0.8–1.3); p for 
linear trend 0.54. 
Age, sex, BMI, 
tobacco 
smoking, alcohol 
use, coffee use, 
asthma 
medication. 
Nandurkar
62
 2004 USA Population-
based 
nested case-
control 
132 81% 16 Questionnaire At least 
weekly 
heartburn or 
acid 
regurgitation 
in the past 
year  
Prevalent Ever smoking, OR 1.8 (95% 
CI 0.5–6.6). 
Ever alcohol, OR 1.0 (95% 
CI 0.3–3.5). 
Age, gender, 
BMI, SCL-90 
somatisation 
score. 
Mohammed
55
 2005 UK Population-
based cross 
sectional 
case-control 
1533 41% 322 Questionnaire At least 
weekly 
heartburn or 
acid 
regurgitation 
during the 
past 
year 
Prevalent Current smoking, OR 1.65 
(95% CI 1.17–2.33). 
Excess alcohol 
consumption (>30 
units/week for men and 
>20 units/week for 
women), OR 2.96 (95% CI 
1.45–6.06). 
Log-BMI, irritable 
bowel syndrome, 
South Asian, 
family history of 
upper 
gastrointestinal 
disease, no 
educational 
attainment, 
excess alcohol, 
current smoking, 
anticholinergic 
drugs. 
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Zheng
56
 2007 Sweden Population-
based cross 
sectional 
case-control 
27717 Not stated 4083 Telephone 
interview 
At least 
weekly 
retrosternal 
pain or 
burning with 
antacid relief 
or radiation 
toward the 
neck or 
regurgitation 
of bitter fluid 
Prevalent Women - monozygotic co-
twin control comparison:   
 
Ever smoking, 1.08 (95% CI 
0.66–1.74). 
 
Cigarettes equivalent/day: 
1–9, OR 0.82 (95% CI 0.45–
1.48); 10–19, OR 1.32 (95% 
CI 0.71–2.44); ≥20, OR 1.10 
(95% CI 0.49–2.45); p for 
trend 0.6390.  
 
Men - monozygotic co-twin 
control comparison: 
 
Ever smoking, OR 1.37 (95% 
CI 0.70–2.66). 
 
Cigarettes equivalent/day: 
1–9, OR 1.21 (95% CI 0.44–
3.27); 10–19, OR 1.05 (95% 
CI 0.47–2.37); ≥20, OR 1.82 
(95% CI 0.86–3.83); p for 
trend 0.1034. 
Women - monozygotic 
co-twin control 
comparison:  
 
Alcohol, OR 0.73 (95% CI 
0.45–1.19).  
 
Absolute alcohol 
grams/month): 1–150, OR 
1.13 (95% CI 0.58–2.17); 
151–1200, OR 0.84 (95% 
CI 0.45–1.59); 1201–
2400, OR 0.48 (95% CI 
0.22–1.04); >2400, OR 
0.31 (95% CI 0.11–0.84); 
p for trend 0.0093.  
 
Men - monozygotic co-
twin control comparison:  
 
Alcohol, OR 0.65 (95% CI 
0.32–1.33).   
 
Absolute alcohol 
(grams/month): 1–150, 
OR 0.75 (95% CI 0.31–
1.79); 151–1200, OR 0.79 
(95% CI 0.34–1.83); 
1201–2400, OR 0.66 (95% 
CI 0.26–1.64); >2400, OR 
0.57 (95% CI 0.24–1.32); 
p for trend 0.1845. 
Year of birth, 
BMI, smoking, 
coffee, physical 
activity at work 
and at leisure 
time, education. 
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Zagari
63
 2008 Italy Population-
based cross 
sectional 
case-control 
1033 67% 245 Questionnaire At least twice 
weekly 
heartburn or 
acid 
regurgitation 
during 
the previous 
12 months 
Prevalent Never smoker, RR 1.0 
(reference); former smoker, 
RR 0.9 (95% CI 0.6-1.2); 
current smoker, RR 0.8 (95% 
CI 0.6-1.2). 
Alcohol consumption: 
none/occasional, RR 1.0 
(reference); weekly, RR 
1.1 (95% CI 0.7-1.5); daily, 
RR 0.8 (95% CI 0.6-1.1). 
Age, sex, BMI, 
smokinger, 
alcohol 
consumption, 
coffee, 
medication (ASA, 
NSAIDs, 
corticosteroids), 
history of peptic 
ulcer disease, 
helicobacter 
pylori infection, 
hiatus hernia. 
Nasseri-
Moghaddam
57
 
2008 Iran Population-
based cross 
sectional 
case-control 
2057 82% 374 Questionnaire At least 
weekly 
heartburn or 
acid 
regurgitation 
in the past  
12 months 
Prevalent Positive smoking, OR 1.83 
(95% CI 1.12–2.99). 
 Age, gender, 
BMI, education 
level, marriage, 
spouse and 
GORD history, 
first relative 
GORD history, 
coffee 
consumption, 
asthma, tea 
consumption,  
NSAID 
consumption. 
Eslick
58
 2009 Australia Population-
based cross 
sectional 
case-control 
672 73% 78 Questionnaire At least 
weekly 
heartburn or 
acid 
regurgitation 
the past 12 
months 
Prevalent Current smoker, OR 2.47 
(95% CI 1.07-5.70). 
 Sex, age, high 
blood pressure, 
diabetes, high 
cholesterol. 
Friedenberg
59
 2010 USA Population-
based cross 
sectional 
case-control 
503 22% 129 Questionnaire Troublesome 
heartburn or 
regurgitation 
≥2 days/week 
or severe 
heartburn or 
regurgitation  
≥1 day/week 
Prevalent Current smoking, OR 1.74 
(95% CI 1.15—2.65). 
 Age, BMI, 
calcium channel 
blocker intake. 
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Pandeya
64
 2011 Australia Population-
based cross 
sectional 
case-control 
1580 51% 174 Questionnaire At least 
weekly 
heartburn or 
acid 
regurgitation 
in the past 
year  
Prevalent Never smoker, OR 1.0 
(reference); current smoker, 
OR 0.83 (95% CI 0.52–1.33); 
ex-smoker, OR 1.30 (95% CI 
0.93–1.83). 
Alcohol consumption 
(drinks/week): Never 
drinkers, OR 1.00 
(reference); <1, OR 1.47 
(95% CI 0.78–2.78); 1–
6.99, OR 1.03 (95% CI 
0.61–1.74); 7–20.99, OR 
1.37 (95% CI 0.79–2.38); 
21 or more, OR 1.33 (95% 
CI 0.72–2.46). 
Age, sex, further 
education, BMI, 
smoking status, 
alcohol, ASA or 
NSAID use in the 
past 5 years, 
physical activity, 
dietary factors 
(hot and spicy 
food 
consumption, 
BBQ meat and its 
doneness, 
frequency of 
takeaway fried, 
home fried food 
consumption). 
Ford
61
 2013 UK Population-
based 
longitudinal 
case-control 
3418 47% 253 Questionnaire At least 
weekly 
heartburn or 
acid 
regurgitation 
over the 
preceding 6 
months 
Incident Tobacco use, OR 1.33 (99% 
CI 0.88-2.02). 
Alcohol use, OR 0.59 (99% 
0.34-1.04). 
Age, gender, 
helicobacter 
pylori status, 
marital status, 
tobacco use, 
alcohol use, 
coffee drinker, 
ethnicity, social 
class, quality of 
life, irritable 
bowel syndrome, 
BMI. 
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Cela
60
 2013 Albania Population-
based cross 
sectional 
case-control 
845 85% 101 Questionnaire At least 
weekly 
heartburn or 
acid 
regurgitation 
during last 
year 
Prevalent Never smoker, OR 1.00 
(reference); current smoker, 
OR 29.3 (95% CI 13.9–61.2); 
former smoker, OR 9.79 
(95% CI 4.22–22.7). 
Alcohol consumption: 
No/occasional, OR 1.00 
(reference); 
moderate/heavy intake, 
OR 1.83 (95% CI 1.10–
3.06). 
Age, sex, 
socioeconomic 
variables, 
behavioural 
factors (smoking, 
alcohol intake, 
physical activity, 
frequency of 
meat and 
consumption, 
frequency of 
fired food 
consumption, 
BMI). 
Hallan
52
 2015 Norway Population-
based 
longitudinal 
nested case-
cohort 
14916 61% 510 Questionnaire Severe (95-
98% at least 
weekly) 
heartburn or 
acid 
regurgitation 
during the 
previous 12 
months 
Incident Never smokers, OR 1.00 
(reference); previous 
smokers, OR 1.37 (95% CI 
1.07–1.76); quitters, OR 
1.73 (95% CI 1.31–2.27); 
current smokers, OR 1.29 
(95% CI 1.00–1.67). 
Alcohol consumption: 
≤weekly, OR 1.00 
(reference); >weekly, OR 
0.91 (95% CI 0.70–1.19). 
Age, sex, BMI 
change, smoking 
status, alcohol 
consumption, 
physical exercise, 
education. 
*In analyses of the risk of GORD with tobacco smoking, tobacco smoking is not included as an adjustment variable. In analyses of the risk of GORD with alcohol consumption, alcohol consumption is not included as 
an adjustment variable. 
 
